Clinical radioimmunodetection: The second decade

Goldenberg, David M.

doi:10.1007/978-1-4613-1497-4_1

Cancer Imaging With Radiolabeled Antibodies

1990

DOI: 10.1007/978-1-4613-1497-4_1

|View full text |Cite

Clinical radioimmunodetection: The second decade

David M. Goldenberg¹

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1993

2001

Publication Types

Select...

Article2

Relationship

Self Cite1

Independent1

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While no totally specific anti-cancer MAbs have been identified, the tumor-associated MAbs which have been produced are being utilized successfully for the detection of neoplasms by external scintigraphy (Goldenberg, 1990) and the use of similar MAbs labeled with high-energy isotopes (Stein et al, 1991;Blumenthal et aL, 1989) or drugs (Shih et al, 1991) for cancer therapy has been successful in experimental animal models and is being actively pursued clinically (DeNardo et al, 1988;Press et al, 1989;. In addition, these MAbs are being applied effectively in generating better understanding of the molecular forms of the tumor-associated antigens which they define (Wreschner et al, 1990;Strnad et aL, 1989).…”

mentioning

confidence: 99%

Specificity and properties of MAb RS7‐3G11 and the antigen defined by this pancarcinoma monoclonal antibody

Stein

Basu

Chen

et al. 1993

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

The murine monoclonal antibody (MAb) RS7-3G11 is an IgG1 with pancarcinoma reactivity, which has been raised against human squamous-cell carcinoma of the lung. Immunoperoxidase staining of frozen tissue sections demonstrated that the antigen defined by RS7-3G11 is present in tumors of the lung, stomach, bladder, breast, ovary, uterus and prostate. The rate and extent of internalization of RS7-3G11 into Calu-3, an adenocarcinoma of the lung cell line, was investigated using unconjugated MAb, followed by fluorescence labelling, and by binding 125I-RS7-3G11 followed by acid removal of surface-bound antibody. Rapid internalization of MAb RS7-3G11 into target cells was observed. Antibody internalization was noted at 30 min, and by 2 hr virtually all MAb RS7-3G11 was internal. Although MAb RS7-3G11 was raised against non-small-cell carcinoma of the lung, ME-180, a cervical-carcinoma cell line, expresses higher quantities of the antigen than the lung-carcinoma cell lines. Due to the higher antigen density in ME-180 cells, this line was used for immunoprecipitation studies and antigen purification. Immunoprecipitation studies using the ME-180 cervical-carcinoma cell line metabolically labeled with [3H]leucine or [3H]glucosamine demonstrated that the antigen defined by RS7-3G11 is a glycoprotein of M(r) 46 kDa. Deglycosylation by treatment with endoglycosidase-F resulted in a protein with a M(r) of 35 kDa. RS7-3G11-antigen was purified from ME-180 tissue-culture cells using affinity-column chromatography. By SDS-PAGE it was seen that the antigen was highly purified. The major band appeared at M(r) of 45 to 48 kDa. This result is in agreement with the immunoprecipitation studies. The broad band observed in the SDS-PAGE is typical of many glycoproteins, and suggests heterogeneity of glycosylation. Chemical and enzymatic treatments of the antigen, followed by Western blot analyses, suggest that the RS7-3G11 antigenic determinant is composed of a conformation-dependent peptide.

show abstract

mentioning

confidence: 99%

Specificity and properties of MAb RS7‐3G11 and the antigen defined by this pancarcinoma monoclonal antibody

Stein

Basu

Chen

et al. 1993

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

Positron emission tomography (PET) and other nuclear medicine modalities in staging gastrointestinal cancer

Bombardieri

Aliberti

Graaf

et al. 2001

Seminars in Surgical Oncology

View full text Add to dashboard Cite

Gastrointestinal (GI) cancers account for the second highest number of new tumor cases and deaths per year in the United States and Western Europe. The most frequently involved sites are, in descending order, the colorectum, stomach, pancreas, liver, bile duct, and esophagus. The most common tumor type is adenocarcinoma. Among the epithelial cancers, great attention has recently been given to the tumors of neuroendocrine origin. These concepts are relevant because nuclear medicine imaging is based on visualization by means of a particular uptake of radiolabelled tracers in cancer cells that concentrate the radioactive signal. This signal is detected and reconstructed in planar or tomographic images. Different radiopharmaceuticals have been proposed for diagnostic application in oncology (such as radiolabelled monoclonal antibodies (MAbs), receptor tracers, and positron-emitting radiopharmaceuticals), and they are currently used as tracers for tumor detection with different modalities and techniques. Most of these techniques demonstrate their clinical usefulness in the diagnosis of GI cancer. This work is not intended to be a comprehensive review of all the extensive experience and possibilities of nuclear medicine for the diagnosis of GI tumors; rather, it aims to summarize the current status of the most important approaches and their main indications in staging GI cancers.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Clinical radioimmunodetection: The second decade

Cited by 2 publications

References 25 publications

Specificity and properties of MAb RS7‐3G11 and the antigen defined by this pancarcinoma monoclonal antibody

Specificity and properties of MAb RS7‐3G11 and the antigen defined by this pancarcinoma monoclonal antibody

Positron emission tomography (PET) and other nuclear medicine modalities in staging gastrointestinal cancer

Contact Info

Product

Resources

About